Clovis Oncology Inc Quick Ratio (CLVS) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Clovis Oncology inc   (NASDAQ: CLVS)

Clovis Oncology Inc 's Quick Ratio

CLVS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 0.08 a new company low.

Within Major Pharmaceutical Preparations industry 604 other companies have achieved higher Quick Ratio than Clovis Oncology Inc in third quarter 2022. While Quick Ratio total ranking in the third quarter 2022 has deteriorated compared to the prior quarter from 2412 to 5155.

Explain Quick Ratio?
How much Cash & cash equivalents CLVS´s has?
What are CLVS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CLVS Quick Ratio (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3
Y / Y Current Liabilities Change 563.63 % -30.25 % -29.67 % -32.29 % -9.09 %
Y / Y Cash & cash equivalent Change -66.08 % -58.92 % -35.97 % -40.3 % -23.48 %
Quick Ratio MRQ 0.08 0.78 1 1.15 1.53
CLVS's Total Ranking # 5155 # 2412 # 4303 # 622 # 1127
Seq. Current Liabilities Change 516.69 % -0.46 % -2.7 % 11.11 % -35.19 %
Seq. Cash & cash equivalent Change -38.34 % -22.63 % -14.77 % -16.59 % -25.31 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 605
Healthcare Sector # 1200
Overall Market # 5155


Quick Ratio Statistics
High Average Low
97.62 20.87 0.08
(Jun 30 2013)   (Sep 30 2022)




Financial Statements
Clovis Oncology Inc 's Current Liabilities $ 748 Millions Visit CLVS's Balance sheet
Clovis Oncology Inc 's Cash & cash equivalent $ 58 Millions Visit CLVS's Balance sheet
Source of CLVS's Sales Visit CLVS's Sales by Geography


Cumulative Clovis Oncology Inc 's Quick Ratio

CLVS's Quick Ratio for the trailling 12 Months

CLVS Quick Ratio

 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 73.12 % -26.68 % -10.27 % 7.6 % 29.11 %
Y / Y Cash & cash equivalent TTM Growth -49.77 % -39.94 % -27.2 % -22.86 % -17.59 %
Quick Ratio TTM 0.37 1.11 1.25 1.26 1.29
Total Ranking TTM # 4676 # 4572 # 4567 # 4560 # 1387
Seq. Current Liabilities TTM Growth 132.05 % -9.86 % -8.79 % -9.26 % -1.72 %
Seq. Cash & cash equivalent TTM Growth -21.35 % -20.31 % -9.33 % -11.62 % -5.95 %

Quick ratio ranking by company, industry and sector >> Back to CLVS Financial Strength Comparisons >> Go to Compare CLVS Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q3 2022 to $747.87 millions, cumulative Quick Ratio decreased to 0.37 below the Clovis Oncology Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 591 other companies have achieved higher Quick Ratio than Clovis Oncology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 4572 to 4676.

Explain Quick Ratio?
How much Cash & cash equivalents CLVS´s has?
What are CLVS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 592
Healthcare Sector # 1192
Within the Market # 4676


trailing twelve months Quick Ratio Statistics
High Average Low
7.23 3.02 0.37
(Sep 30 2018)   (Sep 30 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Organon and Co   0.21 $ 499.000  Millions$ 2,328.000  Millions
Integrated Biopharma Inc  0.20 $ 1.168  Millions$ 5.814  Millions
Therapeuticsmd Inc   0.18 $ 27.080  Millions$ 152.304  Millions
China Pharma Holdings Inc  0.17 $ 2.086  Millions$ 12.628  Millions
Alimera Sciences Inc  0.16 $ 5.514  Millions$ 33.683  Millions
Scienture Holdings Inc   0.16 $ 0.322  Millions$ 2.061  Millions
Sunwin Stevia International Inc.  0.15 $ 2.774  Millions$ 18.579  Millions
International Stem Cell Corporation  0.14 $ 0.666  Millions$ 4.613  Millions
Zyversa Therapeutics Inc   0.13 $ 0.214  Millions$ 1.625  Millions
Bioxytran Inc   0.13 $ 0.374  Millions$ 2.962  Millions
Eagle Pharmaceuticals inc   0.13 $ 15.384  Millions$ 121.828  Millions
Theralink Technologies Inc   0.12 $ 0.416  Millions$ 3.456  Millions
Panbela Therapeutics Inc   0.12 $ 0.941  Millions$ 7.952  Millions
Amneal Pharmaceuticals Inc   0.12 $ 95.891  Millions$ 817.995  Millions
Procaps Group S a   0.12 $ 43.003  Millions$ 368.374  Millions
Gsk Plc  0.11 $ 4,496.267  Millions$ 40,782.821  Millions
Redhill Biopharma Ltd   0.10 $ 19.968  Millions$ 197.454  Millions
Viatris Inc   0.10 $ 646.700  Millions$ 6,521.400  Millions
Orgenesis Inc   0.09 $ 3.015  Millions$ 34.168  Millions
Cv Sciences Inc   0.08 $ 1.139  Millions$ 13.535  Millions
Northwest Biotherapeutics Inc  0.08 $ 9.425  Millions$ 116.128  Millions
Clovis Oncology inc   0.08 $ 58.320  Millions$ 747.870  Millions
Biostax Corp  0.07 $ 0.191  Millions$ 2.793  Millions
Skye Bioscience Inc   0.07 $ 0.420  Millions$ 6.146  Millions
Evofem Biosciences Inc   0.07 $ 7.749  Millions$ 116.707  Millions
Neptune Wellness Solutions Inc   0.06 $ 1.412  Millions$ 23.529  Millions
Serina Therapeutics Inc   0.06 $ 0.466  Millions$ 8.149  Millions
Axim Biotechnologies Inc   0.05 $ 0.169  Millions$ 3.163  Millions
Scopus Biopharma Inc   0.05 $ 0.311  Millions$ 5.920  Millions
Inhibitor Therapeutics Inc   0.05 $ 0.053  Millions$ 1.088  Millions

Date modified: 2026-09-08T15:10:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.